Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease

Authors

  • Dr J. A. Obeso MD,

    Corresponding author
    1. Movement Disorders Unit, Department of Neurology, Clínica Universitaria, University of Navarra, Pamplona, Spain
    • Neurología, Clínica Universitaria, Apdo. 192, Pamplona, Spain
    Search for more papers by this author
  • M. R. Luquin MD,

    1. Movement Disorders Unit, Department of Neurology, Clínica Universitaria, University of Navarra, Pamplona, Spain
    Search for more papers by this author
  • J. M. Martínez Lage MD

    1. Movement Disorders Unit, Department of Neurology, Clínica Universitaria, University of Navarra, Pamplona, Spain
    Search for more papers by this author

Abstract

Seventeen lisuride infusions were given to 12 patients with Parkinson's disease who showed daily oscillations in motor performance. The mean lisuride dose given in continuous intravenous infusion was 0.59 mg (range, 0.3 to 1.0 mg) during a mean period of 9.0 hours (range, 5 to 12 hours). A significant reduction in the number of hours “off” was obtained in all patients. Additional oral levodopa was necessary to maintain normal mobility throughout the infusions. Severe hypotension occurred in 2 patients which required termination of the infusions. Five patients experienced nausea, sweating, and malaise but this did not necessitate interruption of the infusions. Lisuride appears to be one of the best available dopamine agonists for continuous dopaminergic stimulation.

Ancillary